Drug hapten-specific T-cell activation: Current status and unanswered questions.
LC-MS/MS
T-cell activation
drug hypersensitivity
haptenated HLA ligands
peptide synthesis
Journal
Proteomics
ISSN: 1615-9861
Titre abrégé: Proteomics
Pays: Germany
ID NLM: 101092707
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
14
02
2021
received:
24
10
2020
accepted:
16
02
2021
pubmed:
3
3
2021
medline:
28
10
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
Drug haptens are formed from the irreversible, covalent binding of drugs to nucleophilic moieties on proteins, which can warrant adverse reactions in the body including severe delayed-type, T-cell mediated, drug hypersensitivity reactions (DHRs). While three main pathways exist for the activation of T-cells in DHRs, namely the hapten model, the pharmacological interaction model and the altered peptide repertoire model, the exact antigenic determinants responsible have not yet been defined. In recent years, progress has been made using advanced mass spectrometry-based proteomic methods to identify protein carriers and characterise the structure of drug-haptenated proteins. Since genome-wide association studies discovered a link between human leukocyte antigens (HLA) and an individual's susceptibility to DHRs, much effort has been made to define the drug-associated HLA ligands driving T-cell activation, including the elution of natural HLA peptides from HLA molecules and the generation of HLA-binding peptides. In this review, we discuss our current methodology used to design and synthesise drug-modified HLA ligands to investigate their immunogenicity using T-cell models, and thus their implication in drug hypersensitivity.
Identifiants
pubmed: 33651918
doi: 10.1002/pmic.202000267
doi:
Substances chimiques
Haptens
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2000267Informations de copyright
© 2021 The Authors. Proteomics published by Wiley-VCH GmbH.
Références
Schrijvers, R., Gilissen, L., Chiriac, A. M., & Demoly, P. (2015). Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clinical and translational allergy, 5, 31. https://doi.org/10.1186/s13601-015-0073-8
Pallardy, M., & Bechara, R. (2017). Chemical or Drug Hypersensitivity: Is the Immune System Clearing the Danger? Toxicological Sciences, 158(1), 14-22. https://doi.org/10.1093/toxsci/kfx084
Pichler, W. J. (2003). Delayed drug hypersensitivity reactions. Annals of Internal Medicine, 139(8), 683-693. https://doi.org/10.7326/0003-4819-139-8-200310210-00012
Demoly, P., Adkinson, N. F., Brockow, K., Castells, M., Chiriac, A. M., Greenberger, P. A., Khan, D. A., Lang, D. M., Park, H. - S., Pichler, W., Sanchez-Borges, M., Shiohara, T., & Thong, B. Y.-H. (2014). International Consensus on drug allergy. Allergy, 69(4), 420-437. https://doi.org/10.1111/all.12350
Zalewska-Janowska, A., Spiewak, R., & Kowalski, M. L. (2017). Cutaneous Manifestation of Drug Allergy and Hypersensitivity. Immunology and Allergy Clinics of North America, 37(1), 165-181. https://doi.org/10.1016/j.iac.2016.08.006
Malissen, B., Tamoutounour, S., & Henri, S. (2014). The origins and functions of dendritic cells and macrophages in the skin. Nature Reviews Immunology, 14(6), 417-428. https://doi.org/10.1038/nri3683
Modi, A., Desai, M., Shah, S., & Shah, B. (2019). Analysis of Cutaneous Adverse Drug Reactions Reported at the Regional ADR Monitoring Center. Indian Journal of Dermatology, 64(3), 250. https://doi.org/10.4103/ijd.IJD_682_16
Cho, Y.-T., & Chu, C.-Y. (2017). Treatments for Severe Cutaneous Adverse Reactions. Journal immunology research, 2017, 1. https://doi.org/10.1155/2017/1503709
Crisafulli, G., Franceschini, F., Caimmi, S., Bottau, P., Liotti, L., Saretta, F., Bernardini, R., Cardinale, F., & Mori, F. (2019). Mild cutaneous reactions to drugs. Acta bio-medica : Atenei Parmensis, 90(3-S), 36-43. 10.23750/abm.v90i3-S.8159
Pichler, W., Yawalkar, N., Schmid, S., & Helbling, A. (2002). Pathogenesis of drug-induced exanthems. Allergy, 57(10), 884-893. https://doi.org/10.1034/j.1398-9995.2002.02161.x
Yawalkar, N. (2005). Drug-induced exanthems. Toxicology, 209(2), 131-134. https://doi.org/10.1016/j.tox.2004.12.023
Schnyder, B., Frutig, K., Mauri-Hellweg, D., Limat, A., Yawalkar, N., & Pichler, W. J. (1998). T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clinical and Experimental Allergy, 28(11), 1412-1417. https://doi.org/10.1046/j.1365-2222.1998.00419.x
Justiniano, H., Berlingeri-Ramos, A. C., & Sánchez, J. L. (2008). Pattern analysis of drug-induced skin diseases. American Journal of Dermatopathology, 30(4), 352-369. https://doi.org/10.1097/DAD.0b013e3181722ef4
Pichler, W. J (2000). Allergic reactions to drugs: involvement of T cells. Thorax, 55(90002), 61S-65. https://doi.org/10.1136/thorax.55.suppl_2.S61
Hari, Y., Frutig-Schnyder, K., Hurni, M., Yawalkar, N., Zanni, M. P., Schnyder, B., Kappeler, A., Von Greyerz, S., Braathen, L. R., & Pichler, W. J. (2001). T cell involvement in cutaneous drug eruptions. Clinical and Experimental Allergy, 31(9), 1398-1408. https://doi.org/10.1046/j.1365-2222.2001.01164.x
Ye, Y.-M., Hur, G.-Y., Kim, S.-H., Ban, G.-Y., Jee, Y.-K., Naisbitt, D. J., Park, H.-S., & Kim, S.-H. (2017). Drug-specific CD4 + T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. British Journal of Dermatology, 176(2), 378-386. https://doi.org/10.1111/bjd.14839
Kardaun, S. H., Sekula, P., Valeyrie-Allanore, L., Liss, Y., Chu, C. Y., Creamer, D., Sidoroff, A., Naldi, L., Mockenhaupt, M., & Roujeau, J. C. (2013). Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. British Journal of Dermatology, 169(5), 1071-1080. https://doi.org/10.1111/bjd.12501
Omairi, N. E. L., Abourazzak, S., Chaouki, S., Atmani, S., & Hida, M. (2014). Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) induced by carbamazepine: a case report and literature review. The Pan African medical journal, 18, 9-9. 10.11604/pamj.2014.18.9.3799
Choudhary, S., McLeod, M., Torchia, D., & Romanelli, P. (2013). Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. The Journal of clinical and aesthetic dermatology, 6(6), 31-37.
Picard, D., Janela, B., Descamps, V., D'incan, M., Courville, P., Jacquot, S., Rogez, S., Mardivirin, L., Moins-Teisserenc, H., Toubert, A., Benichou, J., Joly, P., & Musette, P. (2010). Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Science Translational Medicine, 2(46), 46ra62. https://doi.org/10.1126/scitranslmed.3001116
Khan, D. A. (2012). Cutaneous drug reactions. Journal of Allergy and Clinical Immunology, 130(5), 1225-1225.e6. https://doi.org/10.1016/j.jaci.2012.08.007
Garcia-Doval, I., Lecleach, L., Bocquet, H., Otero, X.-L., & Roujeau, J.-C. (2000). Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Archives of Dermatology, 136(3), 323-327. https://doi.org/10.1001/archderm.136.3.323
Harr, T., & French, L. E. (2010). Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet journal of rare diseases, 5, 39. https://doi.org/10.1186/1750-1172-5-39
Harris, V., Jackson, C., & Cooper, A. (2016). Review of Toxic Epidermal Necrolysis. International Journal of Molecular Sciences, 17(12), 2135. https://doi.org/10.3390/ijms17122135
Giordano, C., Rivas, J., & Zervos, X. (2014). An Update on Treatment of Drug-Induced Liver Injury. Journal Clinical and translational hepatology, 2(2), 74-79. 10.14218/JCTH.2014.00005
Corsini, A., & Bortolini, M. (2013). Drug-induced liver injury: the role of drug metabolism and transport. Journal of Clinical Pharmacology, 53(5), 463-474. https://doi.org/10.1002/jcph.23
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018). Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives. Current Drug Metabolism, 19(10), 830-838. https://doi.org/10.2174/1389200219666180523095355
Davidson, D. G., & Eastham, W. N. (1966). Acute liver necrosis following overdose of paracetamol. British Medical Journal, 2(5512), 497-499. https://doi.org/10.1136/bmj.2.5512.497
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973). Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. Journal of Pharmacology and Experimental Therapeutics, 187(1), 195-202.
Mazaleuskaya, L. L., Sangkuhl, K., Thorn, C. F., Fitzgerald, G. A., Altman, R. B., & Klein, T. E. (2015). PharmGKB summary. Pharmacogenet Genomics, 25(8), 416-426. https://doi.org/10.1097/FPC.0000000000000150
Jaeschke, H., Xie, Y., & McGill, M. R. (2014). Acetaminophen-induced Liver Injury: from Animal Models to Humans. Journal Clinical and translational hepatology, 2(3), 153-161. 10.14218/JCTH.2014.00014
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017). Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut, 66(6), 1154-1164. https://doi.org/10.1136/gutjnl-2016-313369
Verma, S., & Kaplowitz, N. (2009). Diagnosis, management and prevention of drug-induced liver injury. Gut, 58(11), 1555-1564. https://doi.org/10.1136/gut.2008.163675
Monshi, M. M., Faulkner, L., Gibson, A., Jenkins, R. E., Farrell, J., Earnshaw, C. J., Alfirevic, A., Cederbrant, K., Daly, A. K., French, N., Pirmohamed, M., Park, B. K, & Naisbitt, D. J. (2013). Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology, 57(2), 727-739. https://doi.org/10.1002/hep.26077
Kim, S.-H., Saide, K., Farrell, J., Faulkner, L., Tailor, A., Ogese, M., Daly, A. K., Pirmohamed, M., Park, B. K, & Naisbitt, D. J. (2015). Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. Hepatology, 62(3), 887-899. https://doi.org/10.1002/hep.27912
Bretscher, P. A. (1999). A two-step, two-signal model for the primary activation of precursor helper T cells. PNAS, 96(1), 185-190. https://doi.org/10.1073/pnas.96.1.185
Wieczorek, M., Abualrous, E. T., Sticht, J., Álvaro-Benito, M., Stolzenberg, S., Noé, F., & Freund, C. (2017). Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Frontiers in immunology, 8, 292-292. https://doi.org/10.3389/fimmu.2017.00292
Greenfield, E. A., Nguyen, K. A., & Kuchroo, V. K. (1998). CD28/B7 costimulation: a review. Critical Reviews in Immunology, 18(5), 389-418. https://doi.org/10.1615/critrevimmunol.v18.i5.10
Holt, M. P., Punkosdy, G. A., Glass, D. D., & Shevach, E. M. (2017). TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis. Journal of Immunology, 198(4), 1503-1511. https://doi.org/10.4049/jimmunol.1601670
Landsteiner, K., & Jacobs, J. (1935). Studies on the Sensitization of Animals with Simple Chemical Compounds. Journal of Experimental Medicine, 61(5), 643-656. https://doi.org/10.1084/jem.61.5.643
Pichler, W. J., Naisbitt, D. J., & Park, B. K (2011). Immune pathomechanism of drug hypersensitivity reactions. Journal of Allergy and Clinical Immunology, 127(3 Suppl), S74-S81. https://doi.org/10.1016/j.jaci.2010.11.048
Meng, X., Al-Attar, Z., Yaseen, F. S., Jenkins, R., Earnshaw, C., Whitaker, P., Peckham, D., French, N. S., Naisbitt, D. J., & Park, B. K (2017). Definition of the Nature and Hapten Threshold of the β-Lactam Antigen Required for T Cell Activation In Vitro and in Patients. Journal of immunology (Baltimore, Md.: 1950), 198(11), 4217-4227. https://doi.org/10.4049/jimmunol.1700209
Bechara, R., Maillere, B., Joseph, D., Weaver, R. J., & Pallardy, M. (2019). Identification and characterization of a naïve CD 8+ T cell repertoire for benzylpenicillin. Clinical and Experimental Allergy, 49(5), 636-643. https://doi.org/10.1111/cea.13338
Azoury, M. E., Filì, L., Bechara, R., Scornet, N., De Chaisemartin, L., Weaver, R. J., Claude, N., Maillere, B., Parronchi, P., Joseph, D., & Pallardy, M. (2018). Identification of T-cell epitopes from benzylpenicillin conjugated to human serum albumin and implication in penicillin allergy. Allergy, 73(8), 1662-1672. https://doi.org/10.1111/all.13418
Brander, C., Mauri-Hellweg, D., Bettens, F., Rolli, H., Goldman, M., & Pichler, W. J. (1995). Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. Journal of Immunology, 155(5), 2670-2678.
Tailor, A., Meng, X., Adair, K., Farrell, J., Waddington, J. C., Daly, A., Pirmohamed, M., Dear, G., Park, B. K., & Naisbitt, D. J. (2020). HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. Toxicological Sciences, 178(1), 115-126, https://doi.org/10.1093/toxsci/kfaa128
Naisbitt, D. J., Hough, S. J., Gill, H. J., Pirmohamed, M., Kitteringham, N. R., & Park, B. K. (1999). Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. British Journal of Pharmacology, 126(6), 1393-1407. https://doi.org/10.1038/sj.bjp.0702453
Castrejon, J. L, Berry, N., El-Ghaiesh, S., Gerber, B., Pichler, W. J., Park, B. K, & Naisbitt, D. J. (2010). Stimulation of human T cells with sulfonamides and sulfonamide metabolites. Journal of Allergy and Clinical Immunology, 125(2), 411-418.e4. https://doi.org/10.1016/j.jaci.2009.10.031
Padovan, E., Mauri-Hellweg, D., Pichler, W. J., & Weltzien, H. U. (1996). T cell recognition of penicillin G: structural features determining antigenic specificity. European Journal of Immunology, 26(1), 42-48. https://doi.org/10.1002/eji.1830260107
Pichler, W. J. (2002). Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Current Opinion in Allergy and Clinical Immunology, 2(4), 301-305. https://doi.org/10.1097/00130832-200208000-00003
Kanny, G., Pichler, W., Morisset, M., Franck, P., Marie, B., Kohler, C., Renaudin, J.-M., Beaudouin, E., Laudy, J. S., & Moneret-Vautrin, D. A (2005). T cell-mediated reactions to iodinated contrast media: Evaluation by skin and lymphocyte activation tests. Journal of Allergy and Clinical Immunology, 115(1), 179-185. https://doi.org/10.1016/j.jaci.2004.09.012
Schnyder, B., Mauri-Hellweg, D., Zanni, M., Bettens, F., & Pichler, W. J. (1997). Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. Journal of Clinical Investigation, 100(1), 136-141. https://doi.org/10.1172/JCI119505
Depta, J. P. H., Altznauer, F., Gamerdinger, K., Burkhart, C., Weltzien, H. U., & Pichler, W. J. (2004). Drug interaction with T-cell receptors. Journal of Allergy and Clinical Immunology, 113(3), 519-527. https://doi.org/10.1016/j.jaci.2003.11.030
Wu, Y., Farrell, J., Pirmohamed, M., Park, B. K, & Naisbitt, D. J. (2007). Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. Journal of Allergy and Clinical Immunology, 119(4), 973-981. https://doi.org/10.1016/j.jaci.2006.12.617
Yun, J., Marcaida, M. J., Eriksson, K. K., Jamin, H., Fontana, S., Pichler, W. J., & Yerly, D. (2014). Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. Journal of Immunology, 192(7), 2984-2993. https://doi.org/10.4049/jimmunol.1302306
Zanni, M. P., Von Greyerz, S., Schnyder, B., Brander, K. A., Frutig, K., Hari, Y., Valitutti, S., & Pichler, W. J. (1998). HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. Journal of Clinical Investigation, 102(8), 1591-1598. https://doi.org/10.1172/JCI3544
Schnyder, B., Burkhart, C., Schnyder-Frutig, K., Von Greyerz, S., Naisbitt, D. J., Pirmohamed, M., Park, B. K, & Pichler, W. J. (2000). Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4 + T Cells from Allergic Individuals. The Journal of Immunology, 164(12), 6647-6654. https://doi.org/10.4049/jimmunol.164.12.6647
Chessman, D., Kostenko, L., Lethborg, T., Purcell, A. W., Williamson, N. A., Chen, Z., Kjer-Nielsen, L., Mifsud, N. A., Tait, B. D., Holdsworth, R., Almeida, C. A., Nolan, D., Macdonald, W. A., Archbold, J. K., Kellerher, A. D., Marriott, D., Mallal, S., Bharadwaj, M., Rossjohn, J., & Mccluskey, J. (2008). Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 28(6), 822-832. https://doi.org/10.1016/j.immuni.2008.04.020
Illing, P. T., Vivian, J. P., Dudek, N. L., Kostenko, L., Chen, Z., Bharadwaj, M., Miles, J. J., Kjer-Nielsen, L., Gras, S., Williamson, N. A., Burrows, S. R., Purcell, A. W., Rossjohn, J., & Mccluskey, J. (2012). Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature, 486(7404), 554-558. https://doi.org/10.1038/nature11147
Mallal, S., & Phillips, E. (2012). Abacavir and the altered peptide repertoire model: clinical implications. Journal of the International AIDS Society, 15(6(Suppl 4)). https://doi.org/10.7448/IAS.15.6.18119
Ostrov, D. A., Grant, B. J., Pompeu, Y. A., Sidney, J., Harndahl, M., Southwood, S., Oseroff, C., Lu, S., Jakoncic, J., De Oliveira, C. A. F., Yang, L., Mei, H., Shi, L., Shabanowitz, J., English, A. M., Wriston, A., Lucas, A., Phillips, E., Mallal, S., … Peters, B. (2012). Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the National Academy of Sciences, 109(25), 9959-9964. https://doi.org/10.1073/pnas.1207934109
Pichler, W. J. (2019). Immune pathomechanism and classification of drug hypersensitivity. Allergy, 74(8), 1457-1471. https://doi.org/10.1111/all.13765
Nhim, C., Delluc, S., Halgand, F., De Chaisemartin, L., Weaver, R. J., Claude, N., Joseph, D., Maillère, B., & Pallardy, M. (2013). Identification and frequency of circulating CD4 + T lymphocytes specific to Benzylpenicillin in healthy donors. Allergy, 68(7), 899-905. https://doi.org/10.1111/all.12173
Torres, M. J., Adkinson, N. F, Caubet, J.-C., Khan, D. A., Kidon, M. I., Mendelson, L., Gomes, E. R., Rerkpattanapipat, T., Zhang, S., & Macy, E. (2019). Controversies in Drug Allergy: Beta-Lactam Hypersensitivity Testing. The Journal of Allergy and Clinical Immunology: In Practice, 7(1), 40-45. https://doi.org/10.1016/j.jaip.2018.07.051
Eckstein, R. P., Dowsett, J. F., & Lunzer, M. R. (1993). Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy. Pathology, 25(3), 223-228. https://doi.org/10.3109/00313029309066576
Tune, B. M. (1997). Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention. Pediatric Nephrology, 11(6), 768-772. https://doi.org/10.1007/s004670050386
Kim, T. I., Jeong, K. H., Shin, M. K., & Kim, N. I. (2016). Piperacillin/Tazobactam-Associated Hypersensitivity Syndrome with Overlapping Features of Acute Generalized Exanthematous Pustulosis and Drug-Related Rash with Eosinophilia and Systemic Symptoms Syndrome. Ann Dermatol, 28(1), 98-101. https://doi.org/10.5021/ad.2016.28.1.98
Burrows, J. A., Nissen, L. M., Kirkpatrick, C. M. J., & Bell, S. C. (2007). Beta-lactam allergy in adults with cystic fibrosis. Journal of Cystic Fibrosis, 6(4), 297-303. https://doi.org/10.1016/j.jcf.2006.11.001
Björnsson, E. S. (2017). Drug-induced liver injury due to antibiotics. Scandinavian Journal of Gastroenterology, 52(6-7), 617-623. https://doi.org/10.1080/00365521.2017.1291719
Blanca, M., Perez, E., Garcia, J., Miranda, A., Fernandez, J., Vega, J. M., Terrados, S., Avila, M., Martin, A., & Suau, R. (1988). Anaphylaxis to amoxycillin but good tolerance for benzyl penicillin. Allergy, 43(7), 508-510. https://doi.org/10.1111/j.1398-9995.1988.tb01628.x
Baldo, B. A., Pham, N. H., & Weiner, J. (1995). Detection and side-chain specificity of IgE antibodies to flucloxicillin in allergic subjects. Journal of molecular recognition: JMR, 8(3), 171-177. https://doi.org/10.1002/jmr.300080302
Amali, M. O., Sullivan, A., Jenkins, R. E., Farrell, J., Meng, X., Faulkner, L., Whitaker, P., Peckham, D., Park, B. K., & Naisbitt, D. J. (2017). Detection of drug-responsive B lymphocytes and antidrug IgG in patients with β-lactam hypersensitivity. Allergy, 72(6), 896-907. https://doi.org/10.1111/all.13087
Jenkins, R. E., Meng, X., Elliott, V. L., Kitteringham, N. R., Pirmohamed, M., & Park, B. K (2009). Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics. Clinical applications, 3(6), 720-729. https://doi.org/10.1002/prca.200800222
Ariza, A., Collado, D., Vida, Y., Montañez, M. I., Pérez-Inestrosa, E., Blanca, M., Torres, M. J., Cañada, F. J, & Pérez-Sala, D. (2014). Study of protein haptenation by amoxicillin through the use of a biotinylated antibiotic. Plos One, 9(3), e90891. https://doi.org/10.1371/journal.pone.0090891
Meng, X., Earnshaw, C. J., Tailor, A., Jenkins, R. E., Waddington, J. C., Whitaker, P., French, N. S., Naisbitt, D. J., & Park, B. K (2016). Amoxicillin and Clavulanate Form Chemically and Immunologically Distinct Multiple Haptenic Structures in Patients. Chemical research in toxicology, 29(10), 1762-1772. https://doi.org/10.1021/acs.chemrestox.6b00253
Whitaker, P., Meng, X., Lavergne, S. N., El-Ghaiesh, S., Monshi, M., Earnshaw, C., Peckham, D., Gooi, J., Conway, S., Pirmohamed, M., Jenkins, R. E., Naisbitt, D. J., & Park, B. K (2011). Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. Journal of Immunology, 187(1), 200-211. https://doi.org/10.4049/jimmunol.1100647
Meng, X., Jenkins, R. E., Berry, N. G., Maggs, J. L., Farrell, J., Lane, C. S., Stachulski, A. V., French, N. S., Naisbitt, D. J., Pirmohamed, M., & Park, B. K (2011). Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients. Journal of Pharmacology and Experimental Therapeutics, 338(3), 841-849. https://doi.org/10.1124/jpet.111.183871
Cribb, A. E., & Spielberg, S. P. (1992). Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clinical Pharmacology and Therapeutics, 51(5), 522-526. https://doi.org/10.1038/clpt.1992.57
Meekins, C. V., Sullivan, T. J., & Gruchalla, R. S. (1994). Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. Journal of Allergy and Clinical Immunology, 94(6 Pt 1), 1017-1024. https://doi.org/10.1016/0091-6749(94)90120-1
Reilly, T. P., Lash, L. H., Doll, M. A., Hein, D. W., Woster, P. M., & Svensson, C. K. (2000). A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. Journal of Investigative Dermatology, 114(6), 1164-1173. https://doi.org/10.1046/j.1523-1747.2000.00985.x
Manchanda, T., Hess, D., Dale, L., Ferguson, S. G., & Rieder, M. J. (2002). Haptenation of sulfonamide reactive metabolites to cellular proteins. Molecular Pharmacology, 62(5), 1011-1026. https://doi.org/10.1124/mol.62.5.1011
Summan, M., & Cribb, A. E. (2002). Novel non-labile covalent binding of sulfamethoxazole reactive metabolites to cultured human lymphoid cells. Chemico-Biological Interactions, 142(1-2), 155-173. https://doi.org/10.1016/s0009-2797(02)00060-1
Cheng, L., Stewart, B. J., You, Q., Petersen, D. R., Ware, J. A., Piccotti, J. R., Kawabata, T. T., & Ju, C. (2008). Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo. Molecular Pharmacology, 73(6), 1769-1775. https://doi.org/10.1124/mol.107.043273
Callan, H. E., Jenkins, R. E., Maggs, J. L., Lavergne, S. N., Clarke, S. E., Naisbitt, D. J., & Park, B. K (2009). Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chemical research in toxicology, 22(5), 937-948. https://doi.org/10.1021/tx900034r
Tailor, A., Waddington, J. C., Hamlett, J., Maggs, J., Kafu, L., Farrell, J., Dear, G. J., Whitaker, P., Naisbitt, D. J., Park, K., & Meng, X. (2019). Definition of Haptens Derived from Sulfamethoxazole: In Vitro and in Vivo. Chemical research in toxicology, 32(10), 2095-2106. https://doi.org/10.1021/acs.chemrestox.9b00282
Kosseifi, S. G., Guha, B., Nassour, D. N., Chi, D. S., & Krishnaswamy, G. (2006). The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. Journal of occupational medicine and toxicology (London, England), 1, 9. https://doi.org/10.1186/1745-6673-1-9
Bhaiya, P., Roychowdhury, S., Vyas, P., Doll, M., Hein, D., & Svensson, C. (2006). Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts☆. Toxicology and Applied Pharmacology, 215(2), 158-167. https://doi.org/10.1016/j.taap.2006.02.006
Vyas, P. M., Roychowdhury, S., Khan, F. D., Prisinzano, T. E., Lamba, J., Schuetz, E. G., Blaisdell, J., Goldstein, J. A., Munson, K. L., Hines, R. N., & Svensson, C. K. (2006). Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450. Journal of Pharmacology and Experimental Therapeutics, 319(1), 488-496. https://doi.org/10.1124/jpet.106.105858
Roychowdhury, S., Vyas, P. M., Reilly, T. P., Gaspari, A. A., & Svensson, C. K. (2005). Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. Journal of Pharmacology and Experimental Therapeutics, 314(1), 43-52. https://doi.org/10.1124/jpet.105.086009
Alzahrani, A., Ogese, M., Meng, X., Waddington, J. C., Tailor, A., Farrell, J., Maggs, J. L., Betts, C., Park, B. K, & Naisbitt, D. (2017). Dapsone and Nitroso Dapsone Activation of Naı̈ve T-Cells from Healthy Donors. Chemical research in toxicology, 30(12), 2174-2186. https://doi.org/10.1021/acs.chemrestox.7b00263
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., Fling, M. E., Stocum, M., Bowman, C., Thurmond, L. M., & Roses, A. D. (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet, 359(9312), 1121-1122. https://doi.org/10.1016/S0140-6736(02)08158-8
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., & Christiansen, F. T. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 359(9308), 727-732. https://doi.org/10.1016/s0140-6736(02)07873-x
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D., & Benbow, A. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. New England Journal of Medicine, 358(6), 568-579. https://doi.org/10.1056/NEJMoa0706135
Martin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F. T., Purcell, A. W., Mccluskey, J., & Mallal, S. (2004). Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. PNAS, 101(12), 4180-4185. https://doi.org/10.1073/pnas.0307067101
Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., John, S., Nelson, M. R., Graham, J., Park, B. K., Dillon, J. F., Bernal, W., Cordell, H. J., Pirmohamed, M., Aithal, G. P., & Day, C. P. International, S. A. E. C. (2009). HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics, 41(7), 816-819. https://doi.org/10.1038/ng.379
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004). A marker for Stevens-Johnson syndrome. Nature, 428(6982), 486. https://doi.org/10.1038/428486a
Mullan, K. A., Anderson, A., Illing, P. T., Kwan, P., Purcell, A. W., & Mifsud, N. A. (2019). HLA-associated antiepileptic drug-induced cutaneous adverse reactions. HLA, 93(6), 417-435. https://doi.org/10.1111/tan.13530
Hung, S.-I., Chung, W.-H., Jee, S.-H., Chen, W.-C., Chang, Y.-T., Lee, W.-R., Hu, S.-L., Wu, M.-T., Chen, G.-S., Wong, T.-W., Hsiao, Pa-F, Chen, W.-H., Shih, H.-Y., Fang, Wu-H, Wei, C.-Y., Lou, Y.-H., Huang, Y.-L., Lin, J.-J., & Chen, Y.-T. (2006). Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics, 16(4), 297-306. https://doi.org/10.1097/01.fpc.0000199500.46842.4a
Firbas, C., Jilma, B., Tauber, E., Buerger, V., Jelovcan, S., Lingnau, K., Buschle, M., Frisch, J., & Klade, C. S. (2006). Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine, 24(20), 4343-4353. https://doi.org/10.1016/j.vaccine.2006.03.009
Brennick, C. A., George, M. M., Corwin, W. L., Srivastava, P. K., & Ebrahimi-Nik, H. (2017). Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. Immunotherapy, 9(4), 361-371. https://doi.org/10.2217/imt-2016-0146
Yang, C.-W. O., Hung, S.-I., Juo, C.-G., Lin, Y.-P., Fang, W.-H., Lu, I.-H., Chen, S.-T., & Chen, Y.-T. (2007). HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. Journal of Allergy and Clinical Immunology, 120(4), 870-877. https://doi.org/10.1016/j.jaci.2007.06.017
Waddington, J. C., Meng, X., Illing, P. T., Tailor, A., Adair, K., Whitaker, P., Hamlett, J., Jenkins, R. E., Farrell, J., Berry, N., Purcell, A. W., Naisbitt, D. J., & Park, B. K. (2020). Identification of flucloxacillin-haptenated HLA-B*57:01 ligands: evidence of antigen processing and presentation. Toxicological Sciences, 177, 454-465, https://doi.org/10.1093/toxsci/kfaa124
Padovan, E., Bauer, T., Tongio, M. M., Kalbacher, H., & Weltzien, H. U. (1997). Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. European journal of immunology, 27(6), 1303-1307. https://doi.org/10.1002/eji.1830270602
Ogese, M. O., Jenkins, R. E., Adair, K., Tailor, A., Meng, X., Faulkner, L., Enyindah, B. O., Schofield, A., Diaz-Nieto, R., Ressel, L., Eagle, G. L., Kitteringham, N. R., Goldring, C. E., Park, B. K, Naisbitt, D. J., & Betts, C. (2019). Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System. Hepatology, 70(5), 1732-1749. https://doi.org/10.1002/hep.30701
Rasmussen, M., Fenoy, E., Harndahl, M., Kristensen, A. B., Nielsen, I. K., Nielsen, M., & Buus, S. (2016). Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity. Journal of Immunology, 197(4), 1517-1524. https://doi.org/10.4049/jimmunol.1600582
Sidney, J., Assarsson, E., Moore, C., Ngo, S., Pinilla, C., Sette, A., & Peters, B. (2008). Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome research, 4, 2. https://doi.org/10.1186/1745-7580-4-2
Hsu, S.-C., Chang, C.-P., Tsai, C.-Y., Hsieh, S.-H., Wu-Hsieh, B. A., Lo, Yu-S, & Yang, J.-M. (2012). Steric recognition of T-cell receptor contact residues is required to map mutant epitopes by immunoinformatical programmes. Immunology, 136(2), 139-152. https://doi.org/10.1111/j.1365-2567.2011.03542.x
Hassan, C., Chabrol, E., Jahn, L., Kester, M. G. D., De Ru, A. H., Drijfhout, J. W., Rossjohn, J., Falkenburg, J. H. F, Heemskerk, M. H. M., Gras, S., & Van Veelen, P. A. (2015). Naturally Processed Non-canonical HLA-A*02:01 Presented Peptides*. Journal of Biological Chemistry, 290(5), 2593-2603. https://doi.org/10.1074/jbc.M114.607028
Calis, J. J. A., Maybeno, M., Greenbaum, J. A., Weiskopf, D., De Silva, A. D., Sette, A., Keşmir, C., & Peters, B. (2013). Properties of MHC class I presented peptides that enhance immunogenicity. Plos Computational Biology, 9(10), e1003266. https://doi.org/10.1371/journal.pcbi.1003266
Bilello, J. (2005). The Agony and Ecstasy of “OMIC” Technologies in Drug Development. Current Molecular Medicine, 5(1), 39-52. https://doi.org/10.2174/1566524053152898
Merrifield, R. B. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society, 85(14), 2149-2154. https://doi.org/10.1021/ja00897a025
Amblard, M., Fehrentz, J.-A., Martinez, J., & Subra, G. (2006). Methods and protocols of modern solid phase Peptide synthesis. Molecular Biotechnology, 33(3), 239-254. https://doi.org/10.1385/MB:33:3:239
Wooldridge, L., Lissina, A., Cole, D. K., Van Den Berg, H. A., Price, D. A. &, Sewell, A. K. (2009). Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology, 126(2), 147-164. https://doi.org/10.1111/j.1365-2567.2008.02848.x